AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27412883
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of 20 million allogeneic adipose-derived stem cells in the vaginal walls and fistula tract, followed by a second dose of 40 million if necessary.
Trial: 27412889
Drug: CAR-BCMA T
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR-BCMA T cells (4th dose level: 9 × 10(6) CAR(+) T cells/kg body weight)
Trial: 27412889
Drug: CAR-BCMA T
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR-BCMA T cells (lowest 2 dose levels)
Trial: 27413040
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) for 12 months
Trial: 27413040
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor)
Trial: 27413127
Drug: Diet behavior
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet behavior modification treatment (D group)
Trial: 27413577
Drug: Medication use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication use at discharge
Trial: 27413577
Drug: Medication use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication use at month 6
Trial: 27413577
Drug: Polypharmacy (number
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacy (number of categories of treatments received)
Trial: 27414521
Drug: Oral Shilajit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Shilajit supplementation (250 mg b.i.d. for 8 weeks)
Trial: 27414521
Drug: Oral Shilajit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Shilajit supplementation (250 mg b.i.d. for 8 weeks) with additional 4 weeks of supplementation with exercise
Trial: 27415618
Drug: Supervised physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised physical exercise program (PEP) including cycloergometry/kinesiotherapy plus nutritional therapy
Trial: 27415618
Drug: Nutritional therapy
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional therapy (control)
Trial: 27416639
Drug: FocalyxTx (treatment)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FocalyxTx (treatment)
Trial: 27418646
Drug: Mogamulizumab, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mogamulizumab, an anti-CCR4 monoclonal antibody
Trial: 27418929
Drug: Levothyroxine suppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine suppression therapy (fixed dose)
Trial: 27422150
Drug: Treatment after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment after 8 weeks of acute period treatment in MDD patients
Trial: 27422150
Drug: Longitudinal study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Longitudinal study over 96 weeks including 8-week acute treatment and 88-week stable treatment in MDD patients
Trial: 27422301
Drug: Olaparib 200
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 200 mg bid
Trial: 27422301
Drug: Olaparib 300
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg bid
Trial: 27422301
Drug: Olaparib 300
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg bid (expansion cohort)
Trial: 27422342
Drug: IgG concentrations
RxNorm normalized name: Human IGG
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG concentrations >0.61-5.58μg/mL
Trial: 27422342
Drug: IgG concentrations
RxNorm normalized name: Human IGG
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG concentrations >2.48-17.69μg/mL
Trial: 27423106
Drug: Lacosamide (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide (target dose: 400mg/day by the end of titration) as adjunctive treatment to levetiracetam (LEV, stable dosage of >1000mg/day)
Trial: 27423106
Drug: Lacosamide (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide (target dose: 400mg/day) as adjunctive treatment to levetiracetam (LEV, stable dosage of >1000mg/day)
Trial: 27428731
Drug: Sodium selenite
RxNorm normalized name: Sodium selenite
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Sodium selenite (1000 µg loading dose followed by 1000 µg daily infusion until discharge, max 21 days)
Trial: 27430242
Drug: Atorvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (40 mg/day) for 12 weeks
Trial: 27431901
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 3 measures of immune cell function (neutrophil CD88, monocyte HLA-DR, % regulatory T cells)
Trial: 27432917
Drug: Ceritinib 750
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ceritinib 750 mg/d
Trial: 27433488
Drug: Metformin Extended
RxNorm normalized name: metFORMIN Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin Extended Release (MXR) 2,000 mg daily
Trial: 27435145
Drug: Real-time sensor
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time sensor glucose (SG) for treatment decisions
Trial: 27435882
Drug: Tobramycin inhalation
RxNorm normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin inhalation powder (TIP) for 1 year
Trial: 27436099
Drug: Afatinib 40
RxNorm normalized name: afatinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 40 mg
Trial: 27436285
Drug: Early stress-dose
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early stress-dose steroids
Trial: 27439618
Drug: Narrative Exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative Exposure Therapy (NET) during a ten-week inpatient program
Trial: 27439667
Drug: Patients' beliefs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients' beliefs regarding medication
Trial: 27440259
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g LNS-PL/d (118 kcal) containing essential fatty acids and vitamins and minerals until delivery
Trial: 27440259
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg Fe + 400 μg folic acid/d
Trial: 27440658
Drug: Parent-administered physical
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-administered physical therapy (10 minutes twice a day for 3 weeks from 34 to 36 weeks' PMA)
Trial: 27442600
Drug: Bendamustine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine 40 mg/m², lenalidomide, low-dose dexamethasone
Trial: 27443634
Drug: Chemotherapy (CTh)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CTh)
Trial: 27443634
Drug: Localized CRC
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Localized CRC without chemotherapy (CTh-)
Trial: 27450106
Drug: Standard-of-care therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care therapies
Trial: 27450309
Drug: Histamine-2 Receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine-2 Receptor Antagonists (H2RAs)
Trial: 27453079
Drug: Guanfacine (GUAN)
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guanfacine (GUAN) 1-3 mg/day
Trial: 27453079
Drug: D-methylphenidate extended-release
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-methylphenidate extended-release (DMPH) 5-20 mg/day
Trial: 27453079
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of GUAN and DMPH (COMB)
Trial: 27453080
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with DMPH and GUAN (COMB)
Trial: 30682562
Drug: Melody valve
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melody valve implant
Trial: 27453733
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of insulin injections
Trial: 27453733
Drug: Not filling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not filling insulin prescription due to associated cost
Trial: 27453734
Drug: Metabolic syndrome
RxNorm normalized name: Syndros
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metabolic syndrome (MetS) with minor allele G of ESR1 gene polymorphism (rs9340799)
Trial: 27456232
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (100,000 IU) followed by 400 IU daily for 6 months
Trial: 27456710
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) for none
Trial: 27456710
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) for 1-3 months
Trial: 27456710
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) for 4-12 months
Trial: 27456710
Drug: Low-dose-rate brachytherapy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose-rate brachytherapy (LDR-BT) with BED <178.0 Gy2
Trial: 27456710
Drug: Low-dose-rate brachytherapy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose-rate brachytherapy (LDR-BT) with BED ≥178.0 Gy2
Trial: 27456710
Drug: Low-dose-rate brachytherapy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose-rate brachytherapy (LDR-BT) with or without supplemental EBRT and ADT
Trial: 27457584
Drug: Antibiotic prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prescription rate
Trial: 27457707
Drug: CEP-37250/KHK2804 (0.03-1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEP-37250/KHK2804 (0.03-1.0 mg/kg) intravenously once weekly
Trial: 27458003
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (BV) and AVD (adriamycin, vinblastine, and dacarbazine) followed by 30 Gy involved site radiation therapy (ISRT)
Trial: 27459380
Drug: Client-centered therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Client-centered therapy (CCT)
Trial: 27459537
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor agonist (GLP-1-RA) exenatide for 9 weeks
Trial: 27459537
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor agonist (GLP-1-RA) exenatide
Trial: 27460442
Drug: Vemurafenib 960
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib 960 mg orally twice daily (cohort 1)
Trial: 27460442
Drug: Vemurafenib 960
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib 960 mg orally twice daily (cohort 2)
Trial: 27460571
Drug: Rituximab-based chemotherapy
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab-based chemotherapy (R-chemo)
Trial: 27461255
Drug: Induction neoadjuvant
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction neoadjuvant chemotherapy (NACT)
Trial: 27461255
Drug: Sequential chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemoradiotherapy (CRT)
Trial: 27462386
Drug: Calcipotriene/betamethasone topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriene/betamethasone topical suspension (once-daily)
Trial: 27463733
Drug: Rituximab (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (two infusions of 1000 mg at month 0 and 6, plus 100 mg methylprednisolone)
Trial: 27465398
Drug: Overall weight,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall weight, BMI, fat mass, and subcutaneous adiposity
Trial: 27465647
Drug: Ferumoxytol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferumoxytol (4 mg/kg) administered prior to MRI
Trial: 27466607
Drug: Low serum
RxNorm normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low serum zonulin group (<46.4 ng/mL)
Trial: 27467121
Drug: Sonidegib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonidegib 400 mg q.d.
Trial: 27467121
Drug: Sonidegib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonidegib 600 mg q.d.
Trial: 27467121
Drug: Sonidegib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonidegib 800 mg q.d.
Trial: 27470087
Drug: Low-dose cyclosporine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporine A (CyA) 2 mg/kg body weight per day for 16 weeks
Trial: 27471593
Drug: Lemonade (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lemonade (90 g/L carbohydrates)
Trial: 27471593
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (9 g/L)
Trial: 27472034
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with or without radiotherapy (C/R)
Trial: 27473031
Drug: Alglucosidase alfa
RxNorm normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Alglucosidase alfa treatment
Trial: 27473350
Drug: hCG injection
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG injection
Trial: 27473726
Drug: Standard oncological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oncological therapies
Trial: 27473815
Drug: Temozolomide and
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide and capecitabine-based preoperative chemoradiation therapy (CRT)
Trial: 27474763
Drug: Canakinumab 150
RxNorm normalized name: canakinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab 150 mg every 4 weeks for 4 months
Trial: 27475428
Drug: TPCS2a (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPCS2a (0.25 mg/kg, escalated to 0.5, 1.0, and 1.5 mg/kg) followed by bleomycin (15,000 IU/m²) and laser illumination (652 nm, 60 J/cm²)
Trial: 27475428
Drug: TPCS2a (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPCS2a (1.0 mg/kg)
Trial: 27475428
Drug: TPCS2a (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPCS2a (1.5 mg/kg)
Trial: 27475428
Drug: TPCS2a (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPCS2a (0.25 mg/kg)
Trial: 27475674
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) dose of 36 Gy with a 9-Gy simultaneous in-field boost (SIB) to the positive margins (PM), delivered in 3 fractions.
Trial: 27475674
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) dose escalation plan up to 45 Gy.
Trial: 27476767
Drug: Post-treatment ICG
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment ICG retention test (ICG R)
Trial: 27476790
Drug: HCT-ASCT with
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCT-ASCT with rituximab 375 mg/m(2), carmustine 400 mg/m(2), thiotepa 2×5 mg/kg, and stem cell infusion
Trial: 27476790
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment with five courses of intravenous rituximab 375 mg/m(2) and four courses of intravenous high-dose methotrexate 8000 mg/m(2)
Trial: 27476810
Drug: Piperacillin/tazobactam 4.5 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam 4.5 g 2-3 times daily by intermittent infusion
Trial: 27476810
Drug: Piperacillin trough
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piperacillin trough level of 22.5 mg/L
Trial: 27476810
Drug: Total piperacillin
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Total piperacillin trough levels threshold of 70 mg/L
Trial: 27476810
Drug: Total piperacillin
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Total piperacillin target range ≥70 mg/L
Trial: 27478115
Drug: 1-month triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-month triple antithrombotic therapy (TAT)
Trial: 27478115
Drug: >1-month triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: >1-month triple antithrombotic therapy (TAT)
Trial: 27479177
Drug: NS-018 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NS-018 (300 mg once daily)
Trial: 27479781
Drug: Other phosphate
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other phosphate binders (concomitant therapy)
Trial: 27480288
Drug: Magnetic-controlled capsule
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic-controlled capsule endoscopy (MCCE)
Trial: 27480830
Drug: Leukotriene-modifying drugs
RxNorm normalized name: Leukotriene D4
DrugBank: Leukotriene D4 (DB11858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukotriene-modifying drugs
Trial: 27480830
Drug: Desensitization with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desensitization with daily aspirin therapy
Trial: 27480854
Drug: Daily therapy
RxNorm normalized name: Konsyl Daily Therapy Fiber Laxative 625mg Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily therapy with 250 mg of AZM (n = 77)
Trial: 27480854
Drug: Intermittent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent therapy with 500 mg of AZM three times weekly (n = 89)
Trial: 27480854
Drug: Daily therapy
RxNorm normalized name: Konsyl Daily Therapy Fiber Laxative 625mg Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily therapy with 250 mg of AZM for MABC-LD (n = 55)
Trial: 27483391
Drug: Pimasertib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimasertib (60 mg oral dose)
Trial: 27485208
Drug: Exogenous TRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous TRH administration
Trial: 27485934
Drug: Facebook-based peer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facebook-based peer group intervention for mothers with weekly video-based curriculum and optional face-to-face event.
Trial: 27486034
Drug: Sofosbuvir-velpatasvir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir-velpatasvir (400 mg/100 mg) plus GS-9857 (100 mg) once daily for 6-12 weeks
Trial: 27486034
Drug: Sofosbuvir-velpatasvir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir-velpatasvir (400 mg/100 mg) plus GS-9857 (100 mg) once daily for 6-12 weeks plus ribavirin
Trial: 27486034
Drug: Sofosbuvir-velpatasvir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir-velpatasvir (400 mg/100 mg) plus GS-9857 (100 mg) once daily for 12 weeks
Trial: 27486033
Drug: Sofosbuvir-velpatasvir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir-velpatasvir (400 mg/100 mg fixed-dose combination tablet) and GS-9857 (100 mg) once daily for 6-12 weeks
Trial: 27486340
Drug: PEG 3350
RxNorm normalized name: PEG 3350
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG 3350 ASC (17 g once daily for 14 days)
Trial: 27486524
Drug: ETN 25
RxNorm normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETN 25 mg + MTX
Trial: 27486524
Drug: ETN 50
RxNorm normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETN 50 mg + MTX (Phase I)
Trial: 27486629
Drug: Trastuzumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab with Perioperative Chemotherapy
Trial: 27491288
Drug: Mobile phone
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile phone intervention plus treatment as usual (experimental group)
Trial: 27492790
Drug: Universal decolonization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal decolonization using intranasal mupirocin and chlorhexidine bath (2 cycles, 1 month apart)